SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The Company declared a quarterly dividend of $0.0675 per share on common stock, payable July 30, 2026 to shareholders of record as of July 23, 2026. This is a routine but material capital distribution to shareholders that would affect investor assessment of the registrant's capital allocation and shareholder returns.
View raw filing on EDGAR →Edgewise completed the sale of its sevasemten compound and muscular dystrophy program to Servier Pharmaceuticals for $1.55 billion in upfront cash plus up to $1.1 billion in milestone payments (total consideration up to $2.65 billion), completed on July 10, 2026. This material disposition fundamentally reshapes the company's strategic focus toward cardiovascular programs.
View raw filing on EDGAR →Voyager disclosed positive preclinical GLP toxicology and efficacy data for VY1706 presented at the Alzheimer's Association International Conference, demonstrating favorable tolerability in non-human primates with up to 75% tau protein lowering and broad CNS delivery. This represents a material operational/clinical milestone for a gene therapy program advancing toward human trials (IND clearance received June 2026, dosing planned for H2 2026), affecting investor assessment of the company's pipeline progress and therapeutic potential.
View raw filing on EDGAR →James W. Roquemore, a Board member since 2022 (and previously 1994–2020), passed away on July 9, 2026. The disclosure explicitly states his death and his role as a director. This is a departure event triggered by death, which is material to investors as it affects board composition and governance.
View raw filing on EDGAR →Esperion Therapeutics completed its acquisition by Parent on July 13, 2026, with shareholders receiving $3.16 per share in cash plus contingent value rights (CVRs) with up to $100 million in additional contingent payments, totaling approximately $1.1 billion in aggregate consideration. The transaction resulted in Esperion becoming a wholly owned subsidiary of Parent, with the company's board replaced by Parent's designees and the company's certificate of incorporation and bylaws amended in connection with the merger consummation.
View raw filing on EDGAR →In connection with the merger consummation, Esperion entered into a new Loan Agreement and a Second Supplemental Indenture (which references a Make-Whole Fundamental Change triggered by the merger), creating direct financial obligations as part of the transaction's financing structure.
View raw filing on EDGAR →Esperion notified Nasdaq of the consummation of the merger and requested delisting via Form 25, with the company's shares no longer to be listed on Nasdaq and the company intending to file Form 15 to terminate SEC reporting obligations.
View raw filing on EDGAR →The merger consummation triggered material modifications to security holder rights, including changes to voting, conversion, and other rights as reflected in the amended certificate of incorporation and bylaws.
View raw filing on EDGAR →Tactile Medical announced an exclusive U.S. distribution agreement with ElastiMed for the MyoSleeve wearable compression device targeting VA and DoD patients, with a $3 million upfront payment and commitments to minimum purchase obligations and marketing support. This material strategic partnership expands the company's product portfolio and market reach.
View raw filing on EDGAR →On July 10, 2026, Baosheng Media entered into a securities purchase agreement with High West Partners LLC permitting the issuance of up to US$30,000,000 of ordinary shares at discounted prices (85–97% of VWAP depending on purchase type). This is a classic PIPE (private investment in public equity) arrangement—an unregistered equity issuance at a discount to market price that dilutes existing shareholders. The company must file a prospectus supplement to register the shares, and the investor has agreed not to short-sell during the agreement term, both hallmarks of dilutive equity financing.
View raw filing on EDGAR →Realty Income entered into a Fifth Amended and Restated Credit Agreement on July 10, 2026, increasing unsecured multicurrency revolving credit capacity from $4.0 billion to $5.5 billion (with accordion expansion to $6.5 billion) and establishing two tranches with staggered maturity dates (April 2029 and July 2030). Simultaneously, the company expanded its unsecured commercial paper programs from $3.0 billion to $5.5 billion combined ($2.75 billion U.S. Notes and $2.75 billion Euro Notes), materially enhancing its borrowing capacity and financial flexibility.
View raw filing on EDGAR →FSP completed the sale of two office buildings (6550 and 6560 Greenwood Plaza Boulevard, Englewood, Colorado) totaling approximately 196,236 square feet to University of Colorado Health for $19,356,000 on July 8, 2026, pursuant to a Purchase and Sale Agreement dated May 26, 2026. This is a material disposition of real estate assets, with proceeds used to repay approximately $8.5 million in debt. The transaction is disclosed under Item 2.01 (Completion of Acquisition or Disposition of Assets) and includes pro forma financial statements showing the impact on the registrant's balance sheet and operations.
View raw filing on EDGAR →The 6-K discloses results of an Extraordinary General Meeting held on July 9, 2026, where shareholders voted on and approved multiple resolutions including a Share Consolidation, Post-Share Consolidation Share Capital Increase, Share Capital Reduction and Reorganization, and amendments to the company's Memorandum and Articles of Association. The filing reports quorum (245.4M of 400.6M shares present) and states "All resolutions presented to the shareholders at its Meeting were duly passed," which is a direct shareholder vote result disclosure. These structural and capital changes are material to investors.
View raw filing on EDGAR →The Board approved a final cash dividend, deregistration via Form 15 filing, and a plan for liquidation and dissolution of the Company under Cayman Islands law. This announcement discloses the Company's intent to cease operations, wind down, and dissolve — a terminal event materially threatening the registrant's continued existence. While not a bankruptcy filing, the liquidation and dissolution plan is an existential event that does not fit the specific `bankruptcy_filing` category but clearly belongs in the terminal domain.
View raw filing on EDGAR →This exhibit is a call to assembly announcing an Ordinary and Extraordinary Shareholders' Meeting scheduled for August 20, 2026. The agenda includes approval of a merger with Inversiones y Técnicas Aeroportuarias, S.A.P.I. de C.V., bylaw amendments, extraordinary dividend declarations, and appointment of delegates. While the merger itself would normally be classified as `ma_activity`, this document is the notice convening the meeting to vote on the merger, not the merger agreement or completion announcement. The primary disclosed action is the shareholder meeting call and governance process, making `governance_other` the most appropriate classification. The merger is material but contingent on shareholder approval at the meeting.
View raw filing on EDGAR →This exhibit is an Information Statement disclosing a proposed business combination — the merger of ITA (Inversiones y Técnicas Aeroportuarias) into ASUR to internalize technical assistance and technology transfer services. The transaction involves a capital increase of approximately 7.25 million shares (from 300 million to 307.25 million outstanding shares) to be issued to ITA's shareholders. The document explicitly describes this as an "Integration" and "Business Combination" requiring shareholder approval at an Extraordinary General Shareholders' Meeting on August 20, 2026. This is a material acquisition/merger activity under Item 1.01 or 2.01 equivalent for a foreign private issuer.
View raw filing on EDGAR →The filing discloses both the resignation of Edward M. Weil, Jr. as Chairman and director (effective July 9, 2026) and the appointment of Nicholas S. Schorsch, Jr. as Class III director and Chairman on July 10, 2026. While both events occurred, the principal action disclosed is the appointment of a new Chairman to fill the vacancy, making exec_appointment the most salient classification. Schorsch, Jr. was already serving as CEO since March 2025 and brings substantial real-estate and capital markets experience, making this a material leadership transition.
View raw filing on EDGAR →Fortuna announced the filing of a feasibility study technical report for the Diamba Sud Gold Project in Senegal, supporting a previously announced feasibility study (June 29, 2026). This represents a material operational milestone for a mining company — advancement of a development-stage project through formal feasibility study completion and regulatory filing under NI 43-101. While not a discrete transaction (M&A, debt, equity), it is a significant operational and strategic event that would affect investor assessment of the company's project pipeline and development progress.
View raw filing on EDGAR →Rithm Property Trust disclosed estimated preliminary financial results for Q2 2026, including GAAP comprehensive income of $79–$853K, earnings available for distribution of $(623)–$151K, and book value of $235–$236M.
View raw filing on EDGAR →Rithm Property Trust announced a public offering of common stock and a concurrent private placement by an affiliate of Rithm Capital, with net proceeds intended to fund the acquisition of a $951.1 million portfolio of multifamily transition loans.
View raw filing on EDGAR →Management disclosed unaudited estimates of net asset value per share ($12.48–$12.58), net investment income ($0.35–$0.39 per share), and realized gains/losses (($0.68)–($0.64) per share) for the quarter ended June 30, 2026. This is a financial disclosure of quarterly performance metrics material to investors in a closed-end investment company, but does not constitute a formal earnings release (no press release attached) or fit other specific financial event types. The disclosure is clearly financial in nature and material to investor assessment.
View raw filing on EDGAR →Eagle Point Credit Co disclosed management's unaudited estimates of net asset value per share ($4.45–$4.55), net investment income ($0.15–$0.19 per share), realized gains/losses (($0.80)–($0.76) per share), and foreign currency hedging gains/losses ($0.01–$0.05 per share) for the quarter ended June 30, 2026. These are financial metrics material to investors in a closed-end credit fund, but the disclosure does not constitute a formal earnings release (no full financial statements or press release format) nor fit other specific financial event types. This is a routine quarterly NAV and performance estimate disclosure typical for investment companies, classified as financial_other.
View raw filing on EDGAR →On July 10, 2026, Datavault AI Inc. engaged CBIZ CPAs P.C. as its independent registered public accounting firm, replacing the prior auditor. No disagreements or reportable events occurred with the prior auditor, indicating a routine transition.
View raw filing on EDGAR →The filing discloses the appointment of Barend (Barrie) J. van der Merwe, the current Chief Financial Officer, to the position of Chief Executive Officer effective August 1, 2026, along with his election as Managing Director of the Board. While the section also covers the departure of the interim CEO (Spindler) and appointment of an interim CFO (Deoji), the principal disclosed action centers on the appointment of a new CEO—a material executive leadership change. The detailed compensation terms and board expansion to accommodate this appointment further underscore the materiality of this executive appointment event.
View raw filing on EDGAR →The disclosure centers on an amendment to the Executive Agreement of Lloyd A. Hajdik, the President and CEO, that restructures his severance benefits payable upon qualifying termination events. This is a compensatory arrangement modification affecting a named executive officer's severance terms, which falls squarely within exec_compensation rather than exec_departure (no departure occurred) or exec_appointment (no new role taken).
View raw filing on EDGAR →The disclosure announces clinical and regulatory progress on the REO 033 trial, including activation of clinical sites, pre-identification of patients, and a planned Type D FDA meeting to discuss a registrational pathway expansion (Part B). This is a material operational and strategic milestone for a clinical-stage biotech company advancing its lead candidate toward potential registration, but does not fit the specific categories of earnings release, M&A activity, or other named event types. The regulatory milestone and trial expansion represent significant operational progress affecting investor assessment of development timelines and commercial prospects.
View raw filing on EDGAR →Intapp entered into a new $150 million senior secured revolving credit facility with UBS AG on July 7, 2026, replacing a prior JPMorgan Chase credit agreement. This represents a material refinancing of the company's credit arrangements with customary covenants, security interests, and interest rate terms.
View raw filing on EDGAR →Paul J. Hennessy stepped down as Chief Executive Officer and Board member effective immediately on July 12, 2026, after 4 years as CEO and 11 years on the Board. Rik Powell was appointed as Interim CEO pending a permanent CEO search. The departure was not due to disagreement.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of the Company's 2026 Annual Meeting of Stockholders held on July 8, 2026, including the election of two Class II directors (Curtis Glovier and O. James Sterling) and ratification of Ernst & Young LLP as independent auditor, with specific voting tallies provided for each proposal. The disclosure of shareholder vote results at an annual meeting is a core Item 5.07 event and is material to investors as it confirms board composition and auditor selection.
View raw filing on EDGAR →This press release announces significant exploration drill results at the Eau Claire gold project, including a "best-ever intercept" of 7.01 g/t gold over 21.0 metres and mobilization of a third drill rig. The disclosure is material to investors evaluating the company's exploration progress and resource conversion, but it is an operational/exploration milestone rather than a discrete event fitting the standard taxonomy categories (not earnings, M&A, impairment, or other named event types). The language emphasizes continuity of high-grade mineralization and advancement toward prefeasibility study work, making this an operational exploration update.
View raw filing on EDGAR →Aebi Schmidt disclosed a press release and investor presentation outlining its long-term growth strategy and one-year post-acquisition performance. The disclosure centers on strategic initiatives (product launches, acquisitions, partnerships, facility expansion), synergy achievements ($40m target vs. $25m pre-merger), and forward guidance targeting $3b+ revenue and mid-teen EBITDA margin by 2030. While this is a Regulation FD disclosure (Item 7.01) rather than a specific material event category, the strategic guidance and operational milestones (new product launches, facility openings, major customer contracts) constitute material operational and strategic information affecting investor assessment of the company's growth trajectory and execution capability.
View raw filing on EDGAR →The press release announces the appointment of Dr. Jeff Millard as Executive Vice President, Technical Operations, effective July 13, 2026, and the promotion of Dr. Alex Therien to Executive Vice President, Research & Development. While the release also discloses Amanda Malone's departure as Chief Scientific and Operating Officer, the principal disclosed action is the addition of experienced executive leadership to support the company's transition to late-stage development ahead of the Q4 2026 RESOLVE trial interim release. This is material to investors assessing management capability during a critical growth phase.
View raw filing on EDGAR →Dr. Paulo Fontoura has tendered his resignation from the Board of Directors of Lakefront Biotherapeutics following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA. The principal disclosed action is a director's departure from the board, which is a material governance event affecting the composition of the company's leadership.
View raw filing on EDGAR →SP Strategic Holdings LLC filed an urgent application in the Haifa District Court on July 10, 2026, seeking to enjoin InMode and its directors from proceeding with a special committee's evaluation of an acquisition proposal. The Court issued a temporary restraining order on July 12, 2026, postponing the hearing and blocking any decision on the proposal pending judicial review. This is material litigation that directly impedes a pending M&A transaction and raises governance concerns about director independence, affecting the total mix of information available to investors about the Company's strategic options.
View raw filing on EDGAR →Agenus entered into a Securities Purchase Agreement for a private placement of approximately $85 million in upfront gross proceeds plus up to $255 million upon warrant exercise, totaling up to $340 million. The company will issue 23,035,227 shares of common stock (or pre-funded warrants), Series A purchase warrants for 21,144,277 shares, and Series B purchase warrants for 33,797,214 shares to institutional investors including Commodore Capital, RA Capital, TCGX, Invus, and Ligand, representing substantial dilution to existing shareholders.
View raw filing on EDGAR →The 6-K furnishes three exhibits: (1) a strategic investment in Catalight Capital GP, L.P. for US$78 thousand; (2) unaudited operating results for June 2026 and the six-month period ended June 30, 2026, including revenue, operating income, net income, EBITDA, and EPS; and (3) a monthly sales report with supplementary disclosures on lending, guarantees, and derivative positions. The dominant disclosure is Exhibit 99.2, which presents interim financial results for the first half of 2026 (six months ended June 30, 2026), making this a periodic interim financial report rather than a discrete earnings-release event.
View raw filing on EDGAR →CoreCivic announced an irrevocable notice to redeem in full $238,468,000 principal amount of 4.750% senior notes due 2027 on August 12, 2026. While this is technically a redemption (retirement) of existing debt rather than issuance of new debt, the event involves a material modification of the company's direct financial obligations—accelerating the maturity and requiring significant cash outlay. The company intends to use cash on hand to fund the redemption price including the make-whole premium. This is most closely aligned with debt_issuance as it represents a material capital event affecting the company's debt structure, though it could alternatively be classified as financial_other since it is a debt retirement rather than creation.
View raw filing on EDGAR →Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart in alopecia areata, demonstrating clinically meaningful efficacy (35.3% mean reduction in SALT score, 40% SALT-20 response rate) and a well-tolerated safety profile with no new safety signals, supporting advancement into a registration-directed program in H1 2027.
View raw filing on EDGAR →Third Coast Bancshares announced the closed sale of substantially all assets of its wholly owned subsidiary Third Coast Commercial Capital, Inc. to Gulf Coast Bank & Trust Company for approximately $27.5 million in total consideration, generating a $3.5 million gain and an ongoing revenue share. This is a material asset disposition and divestiture that affects the company's balance sheet and strategic positioning, but does not fit the specific M&A categories (which typically apply to acquisitions, mergers, or changes of control) and is best classified as a financial disposition event.
View raw filing on EDGAR →Victory Capital disclosed its June 2026 AUM and Total Client Assets ($346.1 billion) in a press release filed under Item 8.01. This is a routine monthly/quarterly asset reporting disclosure that provides operational metrics material to investors assessing the firm's business performance and growth trajectory, but does not constitute an earnings release (which would typically include financial results and be filed under Item 2.02). The disclosure is operational in nature and material to understanding the registrant's asset management business.
View raw filing on EDGAR →Q32 Bio announced topline results from Part B of the SIGNAL-AA Phase 2a clinical trial for bempikibart in alopecia areata, demonstrating robust clinical activity (35.3% mean SALT score reduction) and a favorable safety profile. This is a material clinical milestone for a development-stage biopharmaceutical company, representing progress toward potential registration and commercialization of a lead product candidate. While not a traditional earnings release or M&A event, the clinical trial results constitute a material operational and strategic milestone that would affect investor assessment of the company's pipeline and commercial prospects.
View raw filing on EDGAR →Williams announced a $5.34 billion joint venture financing agreement with Blackstone, Apollo, and KKR to support five Power Innovation projects. Under the terms, the partners receive a 49% noncontrolling equity interest in exchange for $5.34 billion in committed capital, while Williams retains 51% interest and operational control. This represents a material capital transaction and partial disposition of equity interests in the Power Innovation projects, which constitutes M&A activity under Item 1.01/2.01 framework, though structured as a joint venture financing rather than a traditional acquisition.
View raw filing on EDGAR →The 6-K announces two onshore financing transactions totaling RMB 740 million: a signed RMB 700 million, 15-year fixed asset loan from Ping An Bank for the Inno Park project at 3.5% fixed rate, and a closed RMB 40 million five-year credit facility from Shenzhen Rural Commercial Bank for the Qianhai project. These represent creation of new direct financial obligations and are explicitly described as refinancing intended to "reduce financing costs, extend the Group's debt maturity profile, preserve near-term cash flow flexibility, and support the Group's long-term capital structure optimization strategy." This is a material capital structure event for the registrant.
View raw filing on EDGAR →This is an announcement of an upcoming earnings call and financial results disclosure for the fourth quarter and full fiscal year 2026, scheduled for July 22, 2026. The exhibit explicitly states "MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026" and confirms that "Financial results will be issued in a press release prior to the call." This is a material disclosure of periodic financial results that would affect a reasonable investor's assessment of the company's financial condition and performance.
View raw filing on EDGAR →The Company amended its Master Repurchase and Securities Contract Agreement with Morgan Stanley to increase available financing from $500 million to $750 million for acquisition and origination of loans, representing a material $250 million increase in available credit facility capacity.
View raw filing on EDGAR →The 6-K cover page explicitly references Exhibit 99.1 titled "Enerflex Ltd. Announces Director Resignation," indicating the principal disclosure is the departure of a director. Director resignations are material governance events that affect the composition of the board and investor assessment of leadership continuity.
View raw filing on EDGAR →The Company effected a 1:200 reverse stock split on July 12, 2026, through an amendment to its Restated Certificate of Incorporation, materially affecting the Company's share structure, trading symbol, and the exercise prices of outstanding options and warrants.
View raw filing on EDGAR →Revelation Biosciences adopted a stockholder rights plan (poison pill) on July 10, 2026, declaring a dividend distribution of one right per outstanding share and filing a Certificate of Designation for Series B Junior Participating Preferred Stock. The rights become exercisable if any person or group acquires 10% or more beneficial ownership without Board approval, entitling other shareholders to purchase shares at a discount as a defensive measure against hostile takeovers.
View raw filing on EDGAR →This Item 5.07 discloses the results of Chewy's July 9, 2026 annual meeting of stockholders, including voting outcomes on four proposals: election of five Class I directors (Raymond Svider, Marco Castelli, Nat Goldhaber, James Nelson, and Martin H. Nesbitt), ratification of Deloitte & Touche LLP as independent auditor, Say on Pay advisory vote, and frequency of future Say on Pay votes. The detailed vote tallies and Board's recommendation to continue annual Say on Pay votes are material governance disclosures that affect investor understanding of board composition and executive compensation oversight.
View raw filing on EDGAR →Trex entered into a National Distribution Agreement with U.S. Lumber Group (SBP) on July 13, 2026, appointing it as the sole and exclusive national distributor of Trex products in the U.S. and Canada effective January 1, 2027, while simultaneously terminating its entire commercial distribution relationship with Boise Cascade Company effective August 12, 2026. This represents a material realignment of the company's distribution network—a core operational and strategic business decision—rather than a discrete M&A transaction, debt issuance, or other financial event. The news release emphasizes this as a key step toward the company's stated priority to "Optimize our Channels for Growth," and the company is raising full-year 2026 guidance in connection with the announcement, indicating materiality to investors.
View raw filing on EDGAR →